SCIENCE

Johnson repositions psychedelics as anti-aging therapy for the healthy

Saturday, March 28, 2026 · from 1 podcast

Bryan Johnson is shifting the psychedelics conversation from mental illness treatment to longevity and performance enhancement for the healthy.
His quantified experiments show psilocybin and 5-MeO-DMT outperform traditional drugs like metformin in lowering blood glucose and inflammation.
The core hypothesis: high-dose psychedelics dismantle the ego-forming default mode network, restoring childlike neuroplasticity and resetting biological aging.

Psychedelics are being rebranded from therapy for the sick to the ultimate biohack for the healthy.

On the All-In podcast, quantified-self pioneer Bryan Johnson laid out a new thesis. His high-dose psilocybin experiments weren't aimed at treating depression, but at triggering a systemic metabolic and neural reset to combat aging. The data, he claims, showed psilocybin outperformed pharmaceutical staples like metformin in driving his blood glucose into an elite percentile and reducing inflammatory markers.

This led him to 5-MeO-DMT, which he described as a 10-second blast into "raw consciousness." The experience, characterized by total surrender, produced what he calls the most profound bliss of his life. The biochemical target for both substances is the brain's default mode network - the circuit responsible for constructing the self and ego, which hardens with age.

Bryan Johnson, All-In with Chamath, Jason, Sacks & Friedberg:
- It had this metabolic reset in the brain where my blood glucose before this was in the top 99.5 percentile of all the population.
- After it went to the top 99.9 percentile. Like to move my blood glucose from that level is very, very hard.

Johnson argues the lasting effect is a return to a childlike, neuroplastic state. He reports waking up laughing from dreams and resolving conflicts without adult defensiveness, suggesting a quieted internal monologue. The goal is to scrub what he calls the "neural barnacles" of a hardened ego.

This reframes ego death not as a spiritual milestone, but as a measurable intervention against the aging process itself. Johnson's quantified approach aims to pivot the cultural conversation from anecdotal wellness to biomarker-driven longevity science.

Health Longevity Society

Source Intelligence

What each podcast actually said

All-In with Chamath, Jason, Sacks & Friedberg

Bryan Johnson: I Just Took the Most Powerful Dose of DMT in the World... Here's What It Was Like • Mar 26

Bryan Johnson argues high-dose psychedelics like psilocybin are a longevity therapy, not just mental health medicine, because they reset metabolic and neural aging pathways.
In a quantified experiment, Johnson found a high 25-milligram dose of psilocybin lowered his blood glucose from the 99.5th to the 99.9th percentile, a shift he says is more dramatic than what metformin achieves.
Johnson's data showed psilocybin altered his gut microbiome and reduced systemic inflammation, targeting a core biological driver of aging.
The key longevity benefit Johnson observes is a durable, childlike neuroplastic state post-experience, evidenced by a quieted internal monologue and simple, non-defensive conflict resolution.
Johnson's quantified approach aims to reframe the psychedelic experience from spiritual anecdote to a measurable biomarker reset of the aging clock.

Also from this episode:

Brain (2)

Johnson describes the brain's default mode network as an engine that constructs the ego and hardens with age, narrowing our experience of reality through patterns of rumination.
Psychedelics like psilocybin work by scrambling the neural traffic patterns of the default mode network, facilitating a systemic neurological reset.

Psychology (1)

Johnson characterizes the 5-MeO-DMT experience as a 10-second blast into a non-visual space of raw consciousness, requiring total surrender of ego to unlock unimaginable bliss.

Health Longevity Psychology